Suppr超能文献

血小板计数低可能是新诊断的急性早幼粒细胞白血病患者严重出血的最重要原因。

Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia.

作者信息

Song Yu-Hua, Peng Peng, Qiao Chun, Zhang Run, Li Jian-Yong, Lu Hua

机构信息

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital.

Department of Hematology, The Second Hospital of Nanjing, Nanjing, People's Republic of China.

出版信息

Onco Targets Ther. 2017 Oct 9;10:4917-4924. doi: 10.2147/OTT.S144438. eCollection 2017.

Abstract

The objective of the current study was to provide more appropriate therapeutic strategies for reducing severe hemorrhaging by assessing the recovery of abnormal coagulation indexes in patients with acute promyelocytic leukemia (APL) during induction therapy. Retrospective analyses of 112 patients newly diagnosed with APL were performed during initial treatment. In our study, the early death rate was 5.36%. Hemorrhage was the leading cause of death during the induction period (4/6). The values of white blood cell count, lactate dehydrogenase, prothrombin time (PT), fibrinogen (Fbg), hemoglobin, and bone marrow leukemic promyelocytes were significantly different in the high-risk group compared to the low/intermediate-risk groups. There were significant differences in the white blood cell count, bone marrow leukemic promyelocytes, platelet (PLT) count, and the levels of lactate dehydrogenase, d-dimer, PT, and Fbg, as well as in FLT3-ITD mutations between patients with major bleeding and those with minor bleeding. Hemostatic variables significantly improved over time during induction therapy. The recovery times of the PLT, PT, and Fbg values were significantly slower in patients with major bleeding than in those with minor bleeding. Specifically, the PLT level in patients with major bleeding was not similar to that in the minor bleeding group until after 4 weeks of treatment. Hemorrhages were the most common cause of induction death in this study. High-risk patients were more prone to serious clinical bleeding symptoms. Patients with major bleeding had more rapid proliferation characteristics and an increased incidence of FLT3-ITD mutations compared to patients with minor bleeding. Hemostatic variables recovered significantly more slowly in patients with major bleeding than in those with minor bleeding. Active induction therapy and blood product infusion are effective in preventing severe bleeding. Our results suggested that low PLT count might be the leading cause of fatal bleeding in patients newly diagnosed with APL.

摘要

本研究的目的是通过评估急性早幼粒细胞白血病(APL)患者诱导治疗期间异常凝血指标的恢复情况,为减少严重出血提供更合适的治疗策略。对112例新诊断为APL的患者在初始治疗期间进行了回顾性分析。在我们的研究中,早期死亡率为5.36%。出血是诱导期死亡的主要原因(4/6)。与低/中危组相比,高危组的白细胞计数、乳酸脱氢酶、凝血酶原时间(PT)、纤维蛋白原(Fbg)、血红蛋白和骨髓白血病早幼粒细胞的值有显著差异。大出血患者和小出血患者在白细胞计数、骨髓白血病早幼粒细胞、血小板(PLT)计数、乳酸脱氢酶、D-二聚体、PT和Fbg水平以及FLT3-ITD突变方面存在显著差异。诱导治疗期间,止血变量随时间显著改善。大出血患者的PLT、PT和Fbg值恢复时间明显慢于小出血患者。具体而言,大出血患者的PLT水平直到治疗4周后才与小出血组相似。出血是本研究中诱导死亡最常见的原因。高危患者更容易出现严重的临床出血症状。与小出血患者相比,大出血患者具有更快的增殖特征和更高的FLT3-ITD突变发生率。大出血患者的止血变量恢复明显慢于小出血患者。积极的诱导治疗和血液制品输注可有效预防严重出血。我们的结果表明,低PLT计数可能是新诊断APL患者致命出血的主要原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/5640392/59ef784a1d75/ott-10-4917Fig1.jpg

相似文献

4
[Correlation between D-Dimer/Fibrinogen Ratio and Bleeding in Patients with Newly Diagnosed Acute Promyelocytic Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Oct;31(5):1340-1344. doi: 10.19746/j.cnki.issn.1009-2137.2023.05.014.
5
[Correlation Analysis between Serum Fibronectin 3 Levels and Early Severe Bleeding in Patients with Newly Diagnosed Acute Promyelocytic Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Aug;32(4):1058-1062. doi: 10.19746/j.cnki.issn.1009-2137.2024.04.013.
6
[Analysis of empirical treatment for newly diagnosed acute promyelocytic leukemia combined with disseminated intravascular coagulation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):315-22. doi: 10.7534/j.issn.1009-2137.2014.02.010.
7
[Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):300-4. doi: 10.7534/j.issn.1009-2137.2013.02.008.
8
Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia.
Eur J Haematol. 2012 Apr;88(4):321-8. doi: 10.1111/j.1600-0609.2011.01747.x. Epub 2012 Feb 2.
9

引用本文的文献

1
Establishment and Application of Warning Scoring System for Bleeding Severity in Patients with Newly Diagnosed Acute Promyelocytic Leukemia.
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251360019. doi: 10.1177/10760296251360019. Epub 2025 Jul 17.
2
Hemostatic abnormalities in acute promyelocytic leukemia: clinical implications and mechanisms.
Curr Opin Hematol. 2025 Jul 8. doi: 10.1097/MOH.0000000000000880.
5
Dysregulated hemostasis in acute promyelocytic leukemia.
Int J Hematol. 2024 May;119(5):526-531. doi: 10.1007/s12185-024-03708-0. Epub 2024 Feb 11.
7
Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia.
Blood Adv. 2023 Sep 26;7(18):5458-5469. doi: 10.1182/bloodadvances.2023010466.

本文引用的文献

1
[Outline of bleeding scores in idopathic immune thrombocytopenia].
Zhonghua Xue Ye Xue Za Zhi. 2015 Dec;36(12):1053-5. doi: 10.3760/cma.j.issn.0253-2727.2015.12.016.
2
The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
Best Pract Res Clin Haematol. 2014 Mar;27(1):11-8. doi: 10.1016/j.beha.2014.04.005. Epub 2014 Apr 13.
3
The unique hemostatic dysfunction in acute promyelocytic leukemia.
Semin Thromb Hemost. 2014 Apr;40(3):332-6. doi: 10.1055/s-0034-1370792. Epub 2014 Mar 3.
4
Optimal approach for high-risk acute promyelocytic leukemia.
Curr Opin Hematol. 2014 Mar;21(2):102-13. doi: 10.1097/MOH.0000000000000025.
5
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.
7
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.
Blood. 2011 May 5;117(18):4716-25. doi: 10.1182/blood-2010-08-302950. Epub 2011 Mar 8.
8
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
Leuk Res. 2011 Jul;35(7):879-84. doi: 10.1016/j.leukres.2010.11.008. Epub 2010 Dec 10.
10
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
J Thromb Haemost. 2010 Apr;8(4):773-82. doi: 10.1111/j.1538-7836.2010.03763.x. Epub 2010 Jan 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验